{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-084663","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.508616+00:00","generated_at":"2026-05-19T14:13:17.971966+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"NewAmsterdam Pharma holds R&D Day; no material updates extracted from filing","bullets":["Company hosted R&D Day on June 11, 2025 in New York City with live webcast.","Presentation furnished as Exhibit 99.1, but no specific pipeline or financial data disclosed in available text.","No concrete numeric updates on obicetrapib trials, revenue, or guidance provided in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-084663","json":"https://secwatch.observer/filing/0000950170-25-084663.json","markdown":"https://secwatch.observer/filing/0000950170-25-084663.md","text":"https://secwatch.observer/filing/0000950170-25-084663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025084663/0000950170-25-084663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025084663/nams-20250611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T14:13:17.971966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}